Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter August 5, 2015

Effect of 6-months’ vitamin D supplementation on residual beta cell function in children with type 1 diabetes: a case control interventional study

  • Atindra Mishra , Devi Dayal EMAIL logo , Naresh Sachdeva and Savita Verma Attri


Background: The aim of this study was to evaluate the effect of short-term vitamin D supplementation on the decline of residual beta cell function (RBCF) in children with type 1 diabetes (T1D).

Methods: The study involved an intervention group (cholecalciferol 2000 IU/day and calcium 25 mg/kg/day for 6 months) comprising 15 children aged 6–12 years and within 1–2 years of diagnosis of T1D. Fifteen age-matched T1D patients were followed up as controls. Stimulated C-peptide levels were estimated at baseline and 6 months.

Results: The mean decrease in stimulated C-peptide levels in the intervention group was lower (–0.048±0.15 ng/mL) as compared with the controls (–0.107±0.23 ng/mL) but did not reach statistical significance (p=0.472). The percent decrease in stimulated C-peptide from baseline to endpoint (8.3% vs. 20.3%, p=0.357) and the monthly decrease (0.008 ng/mL vs. 0.017 ng/mL, p=0.22) were non-significantly lower in the intervention group compared with the control group. Three (20%) patients progressed to undetectable stimulated C-peptide (≤0.01 ng/mL) over the study period in the control group as compared with one (6%) in the intervention group (p-value 0.260).

Conclusions: There was a trend towards lesser decline of RBCF with short term cholecalciferol supplementation in children with T1D. Further larger studies are urgently needed to explore the beneficial effects of the relatively inexpensive vitamin D supplementation on RBCF.

Corresponding author: Dr. Devi Dayal, Additional Professor, Pediatric Endocrinology and Diabetes Unit, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research, Chandigarh-160012, India, Phone: 0091-172-2755657 (O), 0091-172-2772777 (R); Fax: +91-172-2744401, 2745078; E-mail: ;


1. Pugliese A. Advances in the etiology and mechanisms of type 1 diabetes. Discov Med 2014;18:141–50.Search in Google Scholar

2. Sherry NA, Tsai EB, Herold KC. Natural history of beta-cell function in type 1 diabetes. Diabetes 2005;54(Suppl 2):S32–9.10.2337/diabetes.54.suppl_2.S32Search in Google Scholar

3. Oram RA, Jones AG, Besser RE, Knight BA, Shields BM, et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 2014;57:187–91.10.1007/s00125-013-3067-xSearch in Google Scholar PubMed PubMed Central

4. Sørensen JS, Johannesen J, Pociot F, Kristensen K, Thomsen J, et al. Residual β-Cell function 3–6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents. Diabetes Care 2013;36:3454–9.10.2337/dc13-0418Search in Google Scholar PubMed PubMed Central

5. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832–6.10.2337/diacare.26.3.832Search in Google Scholar PubMed

6. Nakanishi K, Watanabe C. Rate of beta-cell destruction in type 1 diabetes influences the development of diabetic retinopathy: protective effect of residual beta-cell function for more than 10 years. J Clin Endocrinol Metab 2008;93:4759–66.10.1210/jc.2008-1209Search in Google Scholar PubMed

7. Bizzarri C, Benevento D, Patera IP, Bongiovanni M, Boiani A, et al. Residual β-cell mass influences growth of prepubertal children with type 1 diabetes. Horm Res Paediatr 2013;80:287–92.10.1159/000355116Search in Google Scholar PubMed

8. Ludvigsson J. Combination therapy for preservation of beta cell function in Type 1 diabetes: new attitudes and strategies are needed! Immunol Lett 2014;159:30–5.10.1016/j.imlet.2014.02.006Search in Google Scholar PubMed

9. Ben Nasr M, D’Addio F, Usuelli V, Tezza S, Abdi R, et al. The rise, fall, and resurgence of immunotherapy in type 1 diabetes. Pharmacol Res 2015;98:31–8.10.1016/j.phrs.2014.07.004Search in Google Scholar PubMed

10. Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, et al. Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes. Diabetes Care 2013;36:4030–5.10.2337/dc13-1074Search in Google Scholar PubMed PubMed Central

11. Strom A, Kolb H, Martin S, Herder C, Simon MC, et al. Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). PLoS One 2012;7:e33108.10.1371/journal.pone.0033108Search in Google Scholar PubMed PubMed Central

12. Narendran P, Solomon TP, Kennedy A, Chimen M, Andrews RC. The time has come to test the beta cell preserving effects of exercise in patients with new onset type 1 diabetes. Diabetologia 2015;58:10–8.10.1007/s00125-014-3412-8Search in Google Scholar PubMed

13. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, et al. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. J Clin Invest 2015;135:448–55.10.1172/JCI78492Search in Google Scholar PubMed PubMed Central

14. Chakhtoura M, Azar ST. The role of vitamin D deficiency in the incidence, progression, and complications of type 1 diabetes mellitus. Int J Endocrinol 2013;2013:148673.10.1155/2013/148673Search in Google Scholar PubMed PubMed Central

15. Van Belle TL, Coppieters KT, Von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 2011;91:79–118.10.1152/physrev.00003.2010Search in Google Scholar PubMed

16. Bizzarri C, Pitocco D, Napoli N, Di SE, Maggi D, et al. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. Diabetes Care 2010;33:1962–3.10.2337/dc10-0814Search in Google Scholar PubMed PubMed Central

17. Walter M, Kaupper T, Adler K, Foersch J, Bonifacio E, et al. No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 2010;33:1443–8.10.2337/dc09-2297Search in Google Scholar PubMed PubMed Central

18. Li X, Liao L, Yan X, Huang G, Lin J, et al. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 2009;25:411–6.10.1002/dmrr.977Search in Google Scholar PubMed

19. Aljabri KS, Bokhari SA, Khan MJ. Glycemic changes after vitamin D supplementation in patients with type 1 diabetes mellitus and vitamin D deficiency. Ann Saudi Med 2010;30:454–8.10.4103/0256-4947.72265Search in Google Scholar PubMed PubMed Central

20. Gabbay MA, Sato MN, Finazzo C, Duarte AJ, Dib SA. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus. Arch Pediatr Adolesc Med 2012;166:601–7.10.1001/archpediatrics.2012.164Search in Google Scholar PubMed

21. Ataie-Jafari A, Loke SC, Rahmat AB, Larijani B, Abbasi F, et al. A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes. Clin Nutr 2013;32:911–7.10.1016/j.clnu.2013.01.012Search in Google Scholar PubMed

22. Picardi A, Visalli N, Lauria A, Suraci C, Buzzetti R, et al. Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes. Horm Metab Res 2006;38:668–72.10.1055/s-2006-954586Search in Google Scholar

23. Craig ME, Hattersley A, Donaghue KC. Definition, epidemiology and classification of diabetes in children and adolescents. ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Pediatric Diabetes 2009; 10(Suppl 12):3–12.10.1111/j.1399-5448.2009.00568.xSearch in Google Scholar

24. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003;77:204–10.10.1093/ajcn/77.1.204Search in Google Scholar

25. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358:1500–3.10.1016/S0140-6736(01)06580-1Search in Google Scholar

26. Gröber U, Spitz J, Reichrath J, Kisters K, Holick MF. Vitamin D: Update 2013: From rickets prophylaxis to general preventive healthcare. Dermatoendocrinol 2013;5:331–47.10.4161/derm.26738Search in Google Scholar PubMed PubMed Central

27. Marwaha RK, Tandon N, Agarwal N, Puri S, Agarwal R, et al. Impact of two regimens of vitamin D supplementation on calcium – vitamin D – PTH axis of schoolgirls of Delhi. Indian Pediatr 2010;47:761–9.10.1007/s13312-010-0116-0Search in Google Scholar PubMed

28. Bhanushali AA, Lajpal N, Kulkarni SS, Chavan SS, Bagadi SS, et al. Frequency of fokI and taqI polymorphism of vitamin D receptor gene in Indian population and its association with 25-hydroxyvitamin D levels. Indian J Hum Genet 2009;15:108–13.10.4103/0971-6866.60186Search in Google Scholar PubMed PubMed Central

29. Morán-Auth Y, Penna-Martinez M, Badenhoop K. VDR FokI polymorphism is associated with a reduced T-helper cell population under vitamin D stimulation in type 1 diabetes patients. J Steroid Biochem Mol Biol 2015;pii: S0960-0760(15)00005–9.10.1016/j.jsbmb.2015.01.003Search in Google Scholar PubMed

30. Onder A, Cetinkaya S, Tunc O, Aycan Z. Evaluation of bone mineral density in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2013;26:1077–81.10.1515/jpem-2012-0369Search in Google Scholar PubMed

Received: 2015-2-17
Accepted: 2015-5-18
Published Online: 2015-8-5
Published in Print: 2016-4-1

©2016 by De Gruyter

Downloaded on 5.6.2023 from
Scroll to top button